MANILA – Ginawaran na ng Food and Drug Administration (FDA) ng emergency use authorization (EUA) ang coronavirus vaccine na Sputnik V, na dinevelop ng ng Russia.
“After a rigorous and thorough review by the regulatory and medical experts of the currently available published and unpublished data, the FDA is granting emergency use authorization to the Sputnik V-GamCoVac COVID-19 vaccine manufactured by Gamaleya National Center of Epidemiology and Micribiology,” anunsyo ni FDA director general Eric Domingo.
Batay sa interim data o paunang datos na ipinasa ng Gamaleya, 91.6% ang efficacy rate laban sa COVID-19 ng Sputnik V.
“Consistent” o hindi rin umano nagbago ang efficacy rate nito nang gamitin sa mga edad 18-anyos pataas.
“The vaccine is given in two components: component is given the first dose, and component two is given as the second dose after three weeks of the first one…. they’re both given 0.5-ml intramuscular injections.”
BREAKING: FDA grants emergency use authorization to the Gamaleya-Sputnik V COVID-19 vaccine of Russia. | @BomboRadyoNews pic.twitter.com/GU2ihe1Gsv
— Christian Yosores (@chrisyosores) March 19, 2021
Ayon kay Domingo puro mild ang adverse events o side effect na naitala mula sa mga nabakunahan ng Russian vaccine. Kapareho ng reaksyon sa ibang bakuna.
“Patients with diabetes, hypertension na controlled, pwede yan. Kapag wala namang acute illness (on the day of vaccination), pwede yan. And a complete history and physical exam will be done.”
“The good thing is that 25% of trial participants actually had commorbids and they also did quite well with the vaccine.”
Una nang sinabi ni Vaccine Czar Carlito Galvez na plano ng pamahalaan na bumili ng hanggang 10-million doses ng Sputnik V.
Magsisimula lang daw ang negosasyon ng Pilipinas at Russia kapag nagawaran na ng EUA ang naturang bakuna.
Sa ngayon apat na bakuna ang may EUA sa Pilipinas, kabilang na rito sa Pfizer-BioNTech, AstraZeneca, Sinovac, at ang kaka-apruba lang na Sputnik V ng Gamaleya.
